Intercept Pharmaceuticals - ICPT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $23.18
Forecasted Upside: 22.01%
Number of Analysts: 8
Breakdown:
0 Sell Ratings
7 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$19.00 As of 11/8/2023 09:00 PM ET

▲ +0.04 (0.21%)

1 month | 3 months | 12 months

Get New Intercept Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ICPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICPT

^$23.18

▲ +22.01% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Intercept Pharmaceuticals in the last 3 months. The average price target is $23.18, with a high forecast of $54.00 and a low forecast of $14.00. The average price target represents a 22.01% upside from the last price of $19.00.

Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in Intercept Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

6/5/2022

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

9/3/2022

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

12/2/2022

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/2/2023

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

5/31/2023

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

8/29/2023

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
1 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

11/27/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/27/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$12.00 ➝ $19.00	Low
9/27/2023	Canaccord Genuity Group	Reiterated Rating	Buy ➝ Hold	$20.00 ➝ $19.00	Low
9/27/2023	HC Wainwright	Downgrade	Buy ➝ Neutral	$19.00	Low
9/26/2023	B. Riley	Downgrade	Buy ➝ Neutral	$15.00 ➝ $19.00	N/A
8/3/2023	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$19.00 ➝ $20.00	Low
8/3/2023	HC Wainwright	Reiterated Rating	Buy	$19.00	Low
7/13/2023	HC Wainwright	Upgrade	Sell ➝ Buy	$8.00 ➝ $19.00	Low
6/29/2023	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$12.00 ➝ $18.00	Low
6/26/2023	Royal Bank of Canada	Lower Target		$14.00 ➝ $13.00	Low
5/30/2023	B. Riley	Lower Target		$30.00 ➝ $15.00	Low
5/23/2023	Bank of America	Lower Target		$17.00 ➝ $14.00	Low
5/23/2023	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low
5/22/2023	Robert W. Baird	Lower Target		$35.00 ➝ $18.00	Low
5/22/2023	HC Wainwright	Downgrade	Neutral ➝ Sell	$8.00	Low
5/17/2023	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
4/28/2023	Raymond James	Boost Target		$28.00 ➝ $31.00	Low
4/10/2023	Piper Sandler	Boost Target	Overweight	$49.00 ➝ $54.00	Low
3/5/2023	Raymond James	Boost Target	Outperform	$26.00 ➝ $28.00	Low
3/3/2023	SVB Leerink	Boost Target	Market Perform	$17.00 ➝ $18.00	Low
3/3/2023	SVB Securities	Boost Target		$17.00 ➝ $18.00	Low
3/3/2023	Royal Bank of Canada	Boost Target	Sector Perform	$17.00 ➝ $19.00	Low
3/3/2023	Needham & Company LLC	Boost Target	Buy	$22.00 ➝ $26.00	Low
2/15/2023	Royal Bank of Canada	Boost Target	Sector Perform	$15.00 ➝ $18.00	Low
1/20/2023	Raymond James	Lower Target	Outperform	$27.00 ➝ $26.00	Low
11/16/2022	HC Wainwright	Lower Target	Neutral	$16.00 ➝ $14.00	Low
10/3/2022	Robert W. Baird	Lower Target	Outperform	$52.00 ➝ $35.00	Low
10/3/2022	SVB Leerink	Lower Target	Market Perform	$21.00 ➝ $17.00	Low
9/30/2022	Piper Sandler	Lower Target		$82.00 ➝ $49.00	Low
8/22/2022	B. Riley	Lower Target	Buy	$30.00 ➝ $28.00	Low
8/9/2022	Cowen	Lower Target		$22.00	Low
8/8/2022	HC Wainwright	Lower Target	Neutral	$18.00 ➝ $16.00	Low
8/4/2022	Raymond James	Boost Target	Outperform	$23.00 ➝ $26.00	N/A
7/8/2022	SVB Leerink	Lower Target	Market Perform	$27.00 ➝ $21.00	N/A
7/8/2022	Needham & Company LLC	Lower Target	Buy	$25.00 ➝ $22.00	N/A
5/10/2022	B. Riley	Boost Target		$30.00 ➝ $32.00	Low
5/9/2022	Raymond James	Lower Target		$44.00 ➝ $23.00	Medium
3/8/2022	Canaccord Genuity Group	Lower Target	Hold	$31.00 ➝ $29.00	Low
3/3/2022	Royal Bank of Canada	Lower Target	Sector Perform	$22.00 ➝ $16.00	High
3/3/2022	Needham & Company LLC	Lower Target	Buy	$30.00 ➝ $25.00	Medium
3/3/2022	SVB Leerink	Lower Target	Market Perform	$30.00 ➝ $27.00	Medium
1/10/2022	B. Riley	Upgrade	Neutral ➝ Buy	$25.00 ➝ $30.00	High
11/8/2021	BMO Capital Markets	Reiterated Rating	Hold	$22.00	Low
11/5/2021	Jefferies Financial Group	Reiterated Rating	Hold	$19.00	Medium
11/4/2021	B. Riley	Boost Target	Neutral	$22.00 ➝ $25.00	High
11/4/2021	Raymond James	Boost Target	Outperform	$40.00 ➝ $44.00	Medium
8/20/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$17.00 ➝ $10.00	Low
8/3/2021	B. Riley	Boost Target	Neutral	$18.00 ➝ $22.00	High
8/2/2021	Wedbush	Lower Target	Outperform	$74.00 ➝ $67.00	Low
8/2/2021	HC Wainwright	Reiterated Rating	Neutral	$21.00 ➝ $18.00	Low
8/1/2021	Robert W. Baird	Reiterated Rating	Buy	$52.00	Low
7/30/2021	Royal Bank of Canada	Boost Target	Sector Perform	$22.00 ➝ $23.00	Low
5/31/2021	SVB Leerink	Reiterated Rating	Hold		Low
5/27/2021	JMP Securities	Reiterated Rating	Hold		Low
5/25/2021	B. Riley	Downgrade	Buy ➝ Neutral	$65.00 ➝ $18.00	High
5/10/2021	Oppenheimer	Lower Target		$33.00 ➝ $20.00	Medium
5/7/2021	The Goldman Sachs Group	Lower Target	Neutral	$29.00 ➝ $18.00	Medium
5/7/2021	Raymond James	Lower Target	Outperform	$52.00 ➝ $40.00	Low
5/7/2021	BMO Capital Markets	Lower Target	Market Perform	$29.00 ➝ $19.00	Low
5/7/2021	Cantor Fitzgerald	Lower Target	Neutral	$45.00 ➝ $23.00	Low
5/6/2021	Stifel Nicolaus	Lower Target	Hold	$29.00 ➝ $16.00	Low
3/12/2021	HC Wainwright	Upgrade	Sell ➝ Neutral	$25.00 ➝ $21.00	Medium
3/2/2021	Needham & Company LLC	Lower Target	Buy	$80.00 ➝ $34.00	Medium
3/1/2021	Wedbush	Lower Target	Outperform	$106.00 ➝ $88.00	Low
3/1/2021	B. Riley	Lower Target	Buy	$74.00 ➝ $65.00	Low
3/1/2021	HC Wainwright	Reiterated Rating	Neutral ➝ Sell	$25.00	Low
3/1/2021	Chardan Capital	Lower Target	Buy	$58.00 ➝ $45.00	Low
2/26/2021	Raymond James	Lower Target	Outperform	$60.00 ➝ $52.00	High
2/23/2021	HC Wainwright	Downgrade	Neutral ➝ Sell	$25.00	Low
1/19/2021	Wedbush	Lower Target	Outperform	$116.00 ➝ $106.00	Low
1/15/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$40.00 ➝ $27.00	High
12/21/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$30.00	Low
11/20/2020	B. Riley	Lower Target	Buy	$97.00 ➝ $74.00	High
11/10/2020	BMO Capital Markets	Lower Target	Market Perform	$56.00 ➝ $38.00	High
11/10/2020	Royal Bank of Canada	Lower Target	Sector Perform	$49.00 ➝ $40.00	High
11/10/2020	Credit Suisse Group	Lower Target	Hold ➝ Neutral	$60.00 ➝ $42.00	High
11/10/2020	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$52.00	High
11/10/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$60.00	High
11/10/2020	SVB Leerink	Lower Target	Market Perform	$50.00 ➝ $48.00	High
11/10/2020	Chardan Capital	Lower Target	Buy	$105.00 ➝ $58.00	High
8/28/2020	Wedbush	Reiterated Rating	Buy	$140.00	Medium
8/11/2020	Royal Bank of Canada	Reiterated Rating	Hold	$57.00	Low
8/11/2020	Oppenheimer	Reiterated Rating	Hold	$54.00	Medium
8/11/2020	Chardan Capital	Reiterated Rating	Buy	$105.00	Medium
8/10/2020	Needham & Company LLC	Initiated Coverage	Buy	$100.00	Medium
8/10/2020	B. Riley	Reiterated Rating	Buy	$97.00	Medium
8/10/2020	Stifel Nicolaus	Boost Target	Hold	$51.00 ➝ $56.00	High
7/30/2020	Piper Sandler	Initiated Coverage	Overweight	$82.00	Medium
7/21/2020	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
6/30/2020	Chardan Capital	Reiterated Rating	Buy	$105.00	Low
6/30/2020	Citigroup	Upgrade	Neutral ➝ Buy	$110.00 ➝ $67.00	High
6/30/2020	SVB Leerink	Lower Target	Market Perform	$89.00 ➝ $50.00	Low
6/30/2020	Needham & Company LLC	Lower Target	Buy	$150.00 ➝ $100.00	Low
6/30/2020	UBS Group	Downgrade	Buy ➝ Neutral	$135.00 ➝ $57.00	Medium
6/30/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$52.00	Medium
6/30/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$57.00	Medium
6/29/2020	B. Riley	Reiterated Rating	Buy	$97.00	Medium
6/29/2020	Wedbush	Reiterated Rating	Buy	$140.00	Medium
6/29/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$137.00 ➝ $59.00	Medium
6/29/2020	Cowen	Downgrade	Outperform ➝ Market Perform	$149.00 ➝ $47.00	Medium
6/29/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High
6/29/2020	Stifel Nicolaus	Lower Target	Hold	$100.00 ➝ $51.00	High
6/29/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$150.00 ➝ $60.00	High
6/29/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$107.00 ➝ $52.00	High
6/29/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$117.00 ➝ $55.00	Medium
6/29/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$124.00 ➝ $46.00	High
6/29/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$146.00 ➝ $46.00	High
6/25/2020	HC Wainwright	Initiated Coverage	Neutral	$92.00	Medium
6/4/2020	BMO Capital Markets	Initiated Coverage	Outperform	$107.00	Low
5/22/2020	Robert W. Baird	Reiterated Rating	Buy	$227.00	High
5/22/2020	B. Riley	Reiterated Rating	Buy	$158.00	N/A
5/22/2020	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$145.00 ➝ $115.00	High
5/14/2020	Wedbush	Reiterated Rating	Buy	$257.00	Medium
5/13/2020	B. Riley	Reiterated Rating	Buy	$158.00	High
5/12/2020	Chardan Capital	Reiterated Rating	Buy	$145.00	High
5/12/2020	Stifel Nicolaus	Lower Target	Hold	$100.00 ➝ $99.00	Medium
5/12/2020	Citigroup	Downgrade	Buy ➝ Neutral	$110.00	Medium
5/11/2020	Needham & Company LLC	Reiterated Rating	Buy	$150.00	High
4/27/2020	Wedbush	Reiterated Rating	Buy	$257.00	High
4/8/2020	Royal Bank of Canada	Reiterated Rating	Buy	$117.00	High
4/2/2020	Chardan Capital	Initiated Coverage	Buy	$145.00	Low
3/26/2020	Wedbush	Reiterated Rating	Buy	$257.00	High
3/26/2020	B. Riley	Reiterated Rating	Buy	$158.00	High
3/5/2020	Bank of America	Initiated Coverage	Neutral	$111.00	Low
2/27/2020	Wedbush	Reiterated Rating	Buy	$257.00	High
2/26/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$186.00	High
2/26/2020	Oppenheimer	Lower Target		$146.00 ➝ $124.00	Low
2/26/2020	Citigroup	Upgrade	Neutral ➝ Buy	$140.00 ➝ $125.00	High
2/20/2020	B. Riley	Reiterated Rating	Buy	$158.00	N/A
2/10/2020	Wedbush	Reiterated Rating	Buy	$257.00	Medium
1/29/2020	Wedbush	Reiterated Rating	Buy	$257.00	Low
1/22/2020	Wedbush	Reiterated Rating	Buy	$257.00	Medium
1/9/2020	B. Riley	Boost Target	Buy	$133.00 ➝ $158.00	Low
1/2/2020	SVB Leerink	Reiterated Rating	Underperform		Medium
1/2/2020	Citigroup	Downgrade	Buy ➝ Neutral	$85.00 ➝ $140.00	High
12/18/2019	Wedbush	Reiterated Rating	Buy	$257.00	Low
12/17/2019	Robert W. Baird	Reiterated Rating	Buy	$227.00	Low
12/17/2019	Needham & Company LLC	Reiterated Rating	Buy	$150.00	Low
12/17/2019	Credit Suisse Group	Reiterated Rating	Outperform	$87.00 ➝ $141.00	Low
12/17/2019	Wells Fargo & Company	Reiterated Rating	Positive ➝ Overweight	$120.00 ➝ $146.00	Low
12/13/2019	B. Riley	Reiterated Rating	Buy	$133.00	High
11/25/2019	Robert W. Baird	Reiterated Rating	Buy	$227.00	High
11/25/2019	Stifel Nicolaus	Boost Target		$86.00 ➝ $102.00	High
11/5/2019	Wedbush	Reiterated Rating	Buy	$243.00	High
11/5/2019	Needham & Company LLC	Reiterated Rating	Buy	$150.00	Low
10/21/2019	Raymond James	Lower Target	Strong-Buy	$148.00 ➝ $147.00	High
10/18/2019	Jefferies Financial Group	Set Target	Buy	$125.00	High
10/18/2019	Credit Suisse Group	Lower Target		$167.00 ➝ $87.00	Low
9/30/2019	Wedbush	Set Target	Buy	$243.00	Low
9/6/2019	Royal Bank of Canada	Set Target	Buy	$135.00	Medium
9/4/2019	Citigroup	Upgrade	Neutral ➝ Buy	$106.00 ➝ $85.00	Medium
8/23/2019	Raymond James	Set Target	Buy	$148.00	N/A
8/12/2019	Stifel Nicolaus	Reiterated Rating	Hold	$86.00	Low
8/8/2019	Royal Bank of Canada	Reiterated Rating	Buy	$135.00	Medium
8/8/2019	Cantor Fitzgerald	Lower Target	Overweight	$191.00 ➝ $186.00	High
8/7/2019	Raymond James	Set Target	Buy	$149.00	Medium
8/6/2019	Oppenheimer	Lower Target	Outperform	$170.00 ➝ $160.00	Medium
7/5/2019	Wedbush	Set Target	Buy	$243.00	Low
6/24/2019	Stifel Nicolaus	Initiated Coverage	Hold ➝ Hold	$89.00 ➝ $89.00	Medium
6/6/2019	Raymond James	Reiterated Rating	Buy		Low
5/13/2019	Wedbush	Reiterated Rating	Outperform	$251.00 ➝ $243.00	Medium
5/8/2019	Cowen	Reiterated Rating	Buy	$149.00	Medium
5/8/2019	B. Riley	Reiterated Rating	Buy ➝ Buy	$169.00	Medium
5/2/2019	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform	$90.02	Medium
4/29/2019	Oppenheimer	Lower Target		$175.00 ➝ $170.00	Medium
4/12/2019	B. Riley	Set Target	Buy	$169.00	High
4/12/2019	Wedbush	Set Target	Buy	$251.00	High
4/12/2019	Wells Fargo & Company	Boost Target	Market Perform	$99.00 ➝ $104.00	High
3/28/2019	UBS Group	Boost Target	Buy	$139.00	Low
3/27/2019	Wedbush	Reiterated Rating	Buy	$251.00	Low
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Low
3/5/2019	Wedbush	Set Target	Buy	$251.00	Medium
3/1/2019	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$130.00	High
2/28/2019	B. Riley	Reiterated Rating	Buy ➝ Buy	$155.00 ➝ $169.00	High
2/28/2019	Raymond James	Set Target	Strong-Buy ➝ Buy	$184.00 ➝ $187.00	High
2/28/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $191.00	High
2/21/2019	Citigroup	Boost Target	Neutral ➝ Neutral	$106.00 ➝ $140.00	High
2/20/2019	Oppenheimer	Boost Target	Outperform	$140.00 ➝ $175.00	High
2/20/2019	Royal Bank of Canada	Boost Target	Sector Perform	$137.00	High
2/20/2019	JMP Securities	Boost Target	Outperform ➝ In-Line	$175.00 ➝ $200.00	High
2/19/2019	Wedbush	Boost Target	Outperform ➝ Outperform	$220.00 ➝ $248.00	High
2/19/2019	Wells Fargo & Company	Boost Target	Market Perform	$75.00 ➝ $127.00	High
2/19/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$170.00	High
2/15/2019	Bank of America	Reiterated Rating	Underperform	$68.00	Low
2/14/2019	Raymond James	Reiterated Rating	Buy		Low
2/12/2019	Credit Suisse Group	Reiterated Rating	Outperform		High
2/4/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$184.00	Low
1/31/2019	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$167.00	High
1/30/2019	JMP Securities	Upgrade	Market Perform ➝ Outperform	$75.00 ➝ $175.00	High
1/28/2019	Jefferies Financial Group	Boost Target	Buy	$150.00	Low
1/24/2019	Needham & Company LLC	Upgrade	Hold ➝ Buy	$150.00	High
1/23/2019	UBS Group	Initiated Coverage	Buy ➝ Buy	$130.00	Low
1/14/2019	Laidlaw	Upgrade	Hold ➝ Buy	$99.00 ➝ $130.00	Low
12/11/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$155.00 ➝ $155.00	High
12/6/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$170.00	Low

(Data available from 11/28/2018 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
8 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

5/2/2023

10 very positive mentions
24 positive mentions
6 negative mentions
2 very negative mentions

Mentions as of

6/1/2023

7 very positive mentions
11 positive mentions
6 negative mentions
0 very negative mentions

Mentions as of

7/1/2023

4 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/31/2023

8 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/30/2023

9 very positive mentions
14 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/29/2023

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/29/2023

2 very positive mentions
2 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/28/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Today's Range

Now: $19.00

$18.98

$19.01

50 Day Range

MA: $18.01

$10.44

$19.00

52 Week Range

Now: $19.00

$8.82

$21.86

Volume

3,963,400 shs

Average Volume

1,362,029 shs

Market Capitalization

$794.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Intercept Pharmaceuticals?: The following Wall Street analysts have issued reports on Intercept Pharmaceuticals in the last twelve months: B. Riley, Bank of America Co., Canaccord Genuity Group Inc., HC Wainwright, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, and SVB Securities.
View the latest analyst ratings for ICPT.
What is the current price target for Intercept Pharmaceuticals?: 11 Wall Street analysts have set twelve-month price targets for Intercept Pharmaceuticals in the last year. Their average twelve-month price target is $23.18, suggesting a possible upside of 22.0%. Piper Sandler has the highest price target set, predicting ICPT will reach $54.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $14.00 for Intercept Pharmaceuticals in the next year.
View the latest price targets for ICPT.
What is the current consensus analyst rating for Intercept Pharmaceuticals?: Intercept Pharmaceuticals currently has 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ICPT, but not buy more shares or sell existing shares.
View the latest ratings for ICPT.
What other companies compete with Intercept Pharmaceuticals?: Other companies that are similar to Intercept Pharmaceuticals include Acelyrin, MiMedx Group, Pliant Therapeutics, Autolus Therapeutics and Apogee Therapeutics. Learn More about companies similar to Intercept Pharmaceuticals.
How do I contact Intercept Pharmaceuticals' investor relations team?: Intercept Pharmaceuticals' physical mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company's listed phone number is (646) 747-1000 and its investor relations email address is [email protected]. The official website for Intercept Pharmaceuticals is www.interceptpharma.com. Learn More about contacing Intercept Pharmaceuticals investor relations.

Intercept Pharmaceuticals - ICPT Stock Price Target and Predictions

Analyst Price Target for ICPT

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.34 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Intercept Pharmaceuticals?

What is the current price target for Intercept Pharmaceuticals?

What is the current consensus analyst rating for Intercept Pharmaceuticals?

What other companies compete with Intercept Pharmaceuticals?

How do I contact Intercept Pharmaceuticals' investor relations team?